STAY UP TO DATE

Inhibition of EZH2 protein could treat multiple myeloma

A study led by Helena Jernberg Wiklund, Uppsala University/SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease. The cancer form multiple myeloma is today incurable and it has been challenging to improve therapy. The study was published in Oncotarget.

Read full press release


STAY UP TO DATE

Last updated: 2017-01-13

Content Responsible: Scilifelab Administration()

Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.
Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.